Indication Prioritization

Leah Hoffmann

The VP of Global Marketing at a F200 pharma company was reviewing a promising drug about to enter Phase II of R&D. The company’s lean team had already completed a broad indication assessment, but they needed help preparing a more detailed opportunity assessment that leveraged scientific, commercial, and regulatory analysis and could feed late-stage development strategies.

Business Talent Group’s talent was an R&D specialist with biopharma business development experience and deep expertise in the drug’s therapeutic area. Leveraging internal and external research resources, he conducted competitive analyses and financial forecasts and prioritized potential indications by patient group. Then, he delivered strategic recommendations on the top three assets for late-stage clinical development.

 

Previous Article
Top 3 Business Problems – July
Top 3 Business Problems – July

At BTG, we help clients address all sorts of business problems. Here are 3 of the most interesting challeng...

Next Article
Assessing an Acquisition’s Market Access Potential
Assessing an Acquisition’s Market Access Potential

A multi-million-dollar pharmaceutical company was in talks to acquire an orphan drug manufacturer with a pi...

Find the perfect market access consultant.

Start a Project